

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representations of the original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

REC'D 01 SEP 2000

WIPO EPO PCT  
DGT

14. 08. 2000

EP 00/07917

(65)

4

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

99116026.8

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN  
THE HAGUE,  
LA HAYE, LE

07/06/00



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

**Blatt 2 der Bescheinigung**  
**Sheet 2 of the certificate**  
**Page 2 de l'attestation**

Anmeldung Nr.:  
Application no.: 99116026.8  
Demande n°:

Anmeldetag:  
Date of filing: 16/08/99  
Date de dépôt:

Anmelder:  
Applicant(s):  
Demandeur(s):  
Sanofi-Synthelabo  
75013 Paris  
FRANCE

Bezeichnung der Erfindung:  
Title of the invention:  
Titre de l'invention:

Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:  
State:  
Pays:

Tag:  
Date:  
Date:

Aktenzeichen:  
File no.  
Numéro de dépôt:

Internationale Patentklassifikation:  
International Patent classification:  
Classification internationale des brevets:

A61K31/39, A61K31/16, A61K31/35, A61K31/42, A61K31/425, A61K31/44, A61K31/445, A61K31/47, A61K31/50, A61K31/505, A61K31/535

Am Anmeldetag benannte Vertragsstaaten:  
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE  
Etats contractants désignés lors du dépôt:

Bemerkungen:  
Remarks:  
Remarques:

USE OF MONOAMINE OXYDASE INHIBITORS FOR THE MANUFACTURE OF  
DRUGS INTENDED FOR THE TREATMENT OF OBESITY

The present invention relates to the use of monoamine  
5 oxydase inhibitors in the manufacture of drugs intended for  
the treatment of obesity.

As described in Cheryl P.Kordik and Allen B.Reitz, J. of  
Med. Chem., Vol 42(2), 181-201, reviewing the various known  
10 strategies to treat obesity, obesity is a "chronic  
condition characterized by overabundance of adipose tissue"  
which "correlates with risks such as high blood pressure,  
coronary heart disease, diabetes, altered steroid  
metabolism, gallstones and certain forms of cancer".

15 It has now been found that reversible selective inhibitors  
of monoamine oxydase A (MAO-A), reversible selective  
inhibitors of monoamine oxydase B (MAO-B) or reversible  
mixed inhibitors of monoamine oxydase A and B (MAO-B and  
20 MAO-A) have activity in decreasing body weight of obese  
patients.

Accordingly the present invention relates to the use of  
reversible selective inhibitors of monoamine oxydase A  
25 (MAO-A), reversible selective inhibitors of monoamine  
oxydase B (MAO-B) or reversible mixed inhibitors of  
monoamine oxydase A and B (MAO-A and MAO-B) for the  
manufacture of drugs intended for the treatment of obesity.

30 The invention therefore further relates to a method of  
treating obesity by administering to a patient in need of  
such treatment a therapeutically effective amount of a  
reversible selective inhibitor of monoamine oxydase A, a  
reversible selective inhibitor of monoamine oxydase B or a  
35 reversible mixed inhibitor of monoamine oxydase A and B.

In fact patients who may be treated may be men and women  
suffering from obesity or overw ight.

high affinity for the A isoform (MAO-A) and great selectivity versus the B isoform (MAO-B), which does not affect reuptake of noradrenaline (NA), serotonin (5-HT) or dopamine (DA).

5 Its chemical synthesis is described in EP 424244.

As reversible MAO-B inhibitor (S)-5-methoxymethyl-3-[6-(4,4,4-trifluorobutoxy)-1,2-benzisoxazol-3-yl]oxazolidin-2-one is preferred.

10

As reversible mixed inhibitor of monoamine oxydase A and B [3(S), 3a(S)]-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1H-oxazolo[3,4-a]quinolin-1-one, (R)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)benzofuran-3-yl]oxazolidin-2-one and (R)-5-methoxymethyl-3-(6-cyclopropylmethoxybenzofuran-3-yl)oxazolidin-2-one are preferred.

15

The active substance according to the invention can be administred to patients in a variety of pharmaceutical forms well-known in the art and particularly in the form of compositions formulated for administration by the oral, injectable, transdermal or rectal route.

20

For oral administration, said compositions can take the form of tablets, dragees or capsules prepared by the conventional techniques using known carriers and excipients, such as binding agents, fillers, lubricants and desintegration agents; they can also be in form of solutions, syrups or suspensions.

25

For administration by the injectable route, the compositions according to the invention may be in the form of injectable solutions, suspensions or emulsions containing an acceptable oily or aqueous liquid carrier.

30

For transdermal administration, the composition can take the form of a patch wherein the drug can be encompassed in a gel, solution, ointment or cream.

35

For rectal administration, the compositions may be in the form of suppositories containing the conventional bases for suppositories.

The following examples relating to pharmacological data and a galenic formulation illustrate the present invention.

Example 1

5

**FEEDING BEHAVIOUR IN FASTED RATS**

Male Wistar rats (Iffa-Credo) were individually housed in polycarbonate cages (48x26.5x21.5 cm) in a temperature- and humidity-controlled animal colony room (20±2°C) with a 12-hour light dark cycle (7 a.m. - 7 p.m.). At least 1 week before the experiment, every animal was often handled and administered saline by oral route in order to avoid stress. Food and water were available ad libitum, and all testing was done in the home cage. Rats were fasted for 24 hour before testing and allowed free access to water. In the morning of the test day, rats were first assigned to either a treatment or a control group then weighed and administered drug or vehicle p.o. (10.30 a.m.) and returned to their home cage. Thirty minutes later, a measured quantity of food (RMM, Harlan Ibérica) was made available to the animals. The food intake is calculated every hour until 6 hours after the drug administration. (W095/11894, Gehlert et al., *J. Pharmacol. Exp. Ther.*, 287, 122-127, 1998).  
 Grams of food consumed by the treated animals every hour was compared to food consumed by the control animals using one-way analysis of variance with a Newman-Keuls' test.

30

Table

35 Effect of befloraxone on food consumption during light period (7 a.m.-7 p.m.) in fasted rats (24 hours). Recording and access to food 11 a.m.-2 p.m.

Table

Effect of 7 days treatment with befloxacatone (10 mg/kg/day, p.o.) on food consumption during dark period (4.30 p.m. - 4.30 a.m.) in fed male Wistar rats

5

	Days of treatment	Food intake (g)	
		Control vehicle p.o. (n=7)	Befloxacatone 10 mg/kg/day, p.o. (n=6)
10	1	3.98 ± 0.63	3.03 ± 0.40
	2	5.91 ± 0.85	3.31 ± 1.00
	3	7.95 ± 0.68	5.32 ± 0.69*
	4	7.35 ± 0.57	6.12 ± 0.50
	5	8.75 ± 0.76	6.10 ± 0.59*
15	6	9.69 ± 0.98	6.98 ± 0.61*
	7	10.1 ± 0.74	6.95 ± 0.75*

\*p < 0.05 vs control (ANOVA test)

20 These results show that in the model using **fasted rats**, befloxacatone (3 mg/kg p.o.) inhibits food intake by about 25% during the first hour after administration of the drug, and in the model of **fed rats** with recording of food consumption in the dark, befloxacatone (10 mg/kg p.o.), once

25 a day for 7 days, inhibits as from the third day, food intake during the first four hours after drug administration.



claims

1. Use of a reversible selective inhibitor of monoamine  
oxydase A, reversible selective inhibitor of monoamine  
5 oxydase B or a reversible mixed inhibitor of monoamine  
oxydase A and B for the manufacture of a medicament  
intended for the treatment of obesity.
2. Use of a reverible mixed inhibitor of monoamine oxydase  
10 A and B according to claim 1.
3. The use according to claim 2 wherein the reversible  
mixed inhibitor of monoamine oxydase A and B is chosen  
among [3(S),3a(S)]-3-methoxymethyl-7-[4,4,4-  
15 trifluorobutoxy]-3,3a,4,5-tetrahydro-1H-oxazolo[3,4-  
a]quinolin-1-one, (R)-5-(methoxymethyl)-3-[6-(4,4,4-  
trifluorobutoxy)benzofuran-3-yl]oxazolidin-2-one and (R)-5-  
methoxymethyl-3-(6-cyclopropylmethoxybenzofuran-3-  
yl)oxazolidin-2-one.
- 20 4. Use of a reversible selective inhibitor of monoamine  
oxydase B according to claim 1.
5. The use according to claim 4 wherein the reversible  
25 selective monoamine oxydase B is chosen among lazabemide,  
milacemide, caroxazone and IFO.
6. The use according to claim 4 wherein the reverible  
selective monoamine oxydase B is (S)-5-methoxymethyl-3-  
30 [6-(4,4,4-trifluorobutoxy)-1,2-benzisoxazol-3-yl]oxazolidin  
-2-one.
7. Use of a reversible selective inihibitor of monoamine  
oxydase A according to claim 1.
- 35 8. The use according to claim 7 wherein the reversible  
selective inhibitor of monoamine oxydase A is chosen among

16-08-1999

EP99116026.8

SPEC

USE OF MONOAMINE OXYDASE INHIBITORS FOR THE MANUFACTURE OF  
DRUGS INTENDED FOR THE TREATMENT OF OBESITY

SANOFI-SYNTHELABO

Abstract :

The present invention relates to the use of reversible selective inhibitors of monoamine oxydase A (MAO-A), reversible selective inhibitors of monoamine oxydase B (MAO-B) or reversible mixed inhibitors of monoamine oxydase A and B (MAO-A and MAO-B) in the manufacture of drugs intended for the treatment of obesity.